Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone

On May 4, 2026, Wolfe Research said the FDA received a study connected April 30 done its Adverse Event Reporting System involving a lawsuit of superior hepatic nonaccomplishment successful a diligent treated with Eli Lilly and Company (NYSE:LLY)’s Foundayo. After contacting the company, Wolfe Research cited Lilly’s effect that it “determined it was not reasonably related to Foundayo,” and said the marketplace absorption appears “overdone,” maintaining an Outperform standing and $1,325 terms target.

On the aforesaid day, RBC Capital noted Eli Lilly shares fell arsenic overmuch arsenic 3% successful pre-market trading pursuing the report, but said the institution provided the aforesaid appraisal that the lawsuit was not linked to Foundayo. The steadfast described the objective information arsenic “clean” and said hepatic events are seen crossed injectable GLP-1s, adding the reported lawsuit “represents baseline noise,” portion maintaining an Outperform standing and a $1,250 terms target.

On May 1, 2026, Morgan Stanley raised its terms people connected Eli Lilly to $1,344 from $1,327 with an Overweight rating, citing Q1 results and higher 2026 guidance supporting its GLP-1 outlook.

On April 30, 2026, Eli Lilly and Company (NYSE:LLY) reported Q1 EPS of $8.55 versus $6.79 statement and gross of $19.8B compared to $17.8B expected. CEO David Ricks said the institution delivered “56% gross growth” and raised full-year guidance, highlighting FDA support of Foundayo and continued pipeline progress.

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceutical products globally.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.